Pharma Mar (MEX:PHM1N) Cyclically Adjusted Revenue per Share: MXN0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PHM1N Pharma Mar SA MEX:PHM1N
68 GF Score
Price MXN1,608.38
GF Value MXN1,734.34
! 2 Warning Signs
View Full Analysis

What is Pharma Mar Cyclically Adjusted Revenue per Share?

Pharma Mar MEX:PHM1N 68 Cyclically Adjusted Revenue per Share is MXN0.00 as of Jun. 2026. GuruFocus rates MEX:PHM1N with a GF Score™ of 68/100 and a GF Value™ of MXN1,734.34. The stock has 2 warning signs investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pharma Mar's adjusted revenue per share for the three months ended in Jun. 2026 was MXN57.621. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Pharma Mar's average Cyclically Adjusted Revenue Growth Rate was 4.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pharma Mar was 6.30% per year. The lowest was -0.50% per year. And the median was 3.60% per year.

As of today (2026-08-10), Pharma Mar's current stock price is MXN1608.38. Pharma Mar's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN0.00. Pharma Mar's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharma Mar was 14.45. The lowest was 1.21. And the median was 5.11.


Pharma Mar  (MEX:PHM1N) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharma Mar was 14.45. The lowest was 1.21. And the median was 5.11.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pharma Mar Cyclically Adjusted Revenue per Share Related Terms


Pharma Mar Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Pharma Mar's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Mar Cyclically Adjusted Revenue per Share Chart

Pharma Mar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 286.87 268.40 432.24 230.57 255.97

Pharma Mar Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 233.87 201.74 255.97 221.01 0.00

MEX:PHM1N vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Pharma Mar's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Mar Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Cyclically Adjusted PS Ratio falls into.


MEX:PHM1N
68GF Score
Pharma Mar SA MEX:PHM1N
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Mar Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pharma Mar's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=57.621/131.3300*131.3300
=57.621

Current CPI (Jun. 2026) = 131.3300.

Pharma Mar Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 55.880 99.737 73.581
201612 48.802 101.842 62.932
201703 49.724 100.896 64.723
201706 56.743 101.848 73.168
201709 31.676 101.524 40.976
201712 44.096 102.975 56.238
201803 33.817 102.122 43.489
201806 48.035 104.165 60.562
201809 26.495 103.818 33.516
201812 24.217 104.193 30.524
201903 23.079 103.488 29.288
201906 25.855 104.612 32.459
201909 24.830 103.905 31.384
201912 26.452 105.015 33.081
202003 139.398 103.469 176.934
202006 98.548 104.254 124.142
202009 76.021 103.521 96.443
202012 63.870 104.456 80.302
202103 68.720 104.857 86.069
202106 62.678 107.102 76.856
202109 55.923 107.669 68.213
202112 115.187 111.298 135.919
202203 64.754 115.153 73.851
202206 56.714 118.044 63.097
202209 48.541 117.221 54.384
202212 57.953 117.650 64.691
202303 36.487 118.948 40.285
202306 47.745 120.278 52.132
202309 39.132 121.343 42.353
202312 42.509 121.300 46.024
202403 39.118 122.762 41.848
202406 48.204 124.409 50.886
202409 57.424 123.121 61.253
202412 116.824 124.753 122.983
202503 49.099 125.531 51.367
202506 70.256 127.251 72.508
202509 44.709 126.840 46.292
202512 155.859 128.400 159.416
202603 51.677 129.860 52.262
202606 57.621 131.330 57.621

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN0.00 mean?
Pharma Mar (MEX:PHM1N) has a Cyclically Adjusted Revenue per Share of MXN0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pharma Mar and its competitors.
Is Pharma Mar's Cyclically Adjusted Revenue per Share too high?
Pharma Mar's current Cyclically Adjusted Revenue per Share is MXN0.00. Overall, Pharma Mar has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Pharma Mar's Cyclically Adjusted Revenue per Share of MXN0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pharma Mar and its competitors. Pharma Mar's current Cyclically Adjusted Revenue per Share is MXN0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Pharma Mar (MEX:PHM1N) has a current Cyclically Adjusted Revenue per Share of MXN0.00. The stock's GF Value™ is MXN1,734.34, compared to a current price of MXN1,608.38 — trading 7.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN0.00. Pharma Mar's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Pharma Mar (MEX:PHM1N), the current Cyclically Adjusted Revenue per Share is MXN0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharma Mar (MEX:PHM1N) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued. The current stock price of MXN1,608.38 is trading 7.3% below its estimated GF Value™ of MXN1,734.34.

Key valuation signals for MEX:PHM1N:

  • Cyclically Adjusted Revenue per Share: MXN0.00
  • GF Value™: MXN1,734.34 vs. price of MXN1,608.38 (7.3% below fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the MEX:PHM1N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharma Mar Business Description

Address Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
68GF Score

Get the complete analysis for MEX:PHM1N

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,608.38
Price
MXN1,734.34
GF Value